Arcutis Biotherapeutics Inc Ordinary Shares ARQT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
New Data Shows ZORYVE® (Roflumilast) Cream 0.15% Provided Consistent Improvement of Atopic Dermatitis in Individuals With Diverse Skin Types
-
FDA Accepts Arcutis’ Supplemental New Drug Application for ZORYVE® (roflumilast) Foam for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over
-
Arcutis Announces Publication of ZORYVE® (roflumilast) Cream 0.15% Pivotal Results from Phase 3 INTEGUMENT-1 and -2 Trials in Mild to Moderate Atopic Dermatitis in Journal of American Medical Association Dermatology
-
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Arcutis Completes Enrollment of Phase 1b Alopecia Areata Study Evaluating ARQ-255
-
Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.05% Show Durable and Improved Efficacy Over Time and Favorable Safety Profile in Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis
-
Arcutis to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
-
CORRECTION – Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update
Trading Information
- Previous Close Price
- $9.10
- Day Range
- $9.11–9.68
- 52-Week Range
- $1.76–13.17
- Bid/Ask
- $9.16 / $9.19
- Market Cap
- $1.07 Bil
- Volume/Avg
- 2.2 Mil / 2.3 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 6.75
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 296
- Website
- https://www.arcutis.com
Comparables
Valuation
|
Metric
|
ARQT
|
EXEL
|
REGN
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 17.20 | 23.34 |
Price/Book Value | 5.72 | 3.53 | 4.06 |
Price/Sales | 6.75 | 4.01 | 8.82 |
Price/Cash Flow | — | 16.42 | 24.83 |
Price/Earnings
ARQT
EXEL
REGN
Financial Strength
|
Metric
|
ARQT
|
EXEL
|
REGN
|
|---|---|---|---|
Quick Ratio | 7.90 | 4.05 | 4.43 |
Current Ratio | 8.46 | 4.27 | 5.44 |
Interest Coverage | −5.45 | — | 60.16 |
Quick Ratio
ARQT
EXEL
REGN
Profitability
|
Metric
|
ARQT
|
EXEL
|
REGN
|
|---|---|---|---|
Return on Assets (Normalized) | −44.22% | 14.82% | 15.52% |
Return on Equity (Normalized) | −132.42% | 19.05% | 19.84% |
Return on Invested Capital (Normalized) | −42.92% | 14.99% | 16.15% |
Return on Assets
ARQT
EXEL
REGN
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Bmbpclznfz | Kbyxh | $554.5 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Lhdyxqq | Vbshk | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Rfdggngz | Lfxlwhz | $114.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Xdwbnhblj | Rqchbt | $35.2 Bil | |||
| argenx SE ADR
ARGX
| Jmpdmtdnw | Xflf | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Jymxstgx | Fyyw | $28.0 Bil | |||
| Moderna Inc
MRNA
| Yhfgzjnmy | Lmx | $24.6 Bil | |||
| United Therapeutics Corp
UTHR
| Znhhsqy | Nvt | $15.9 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Zwnpfnwm | Gdwjxgz | $13.4 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Fskncsnvsd | Hhcjcks | $12.6 Bil |
United States